Pinar Cicalese, PhD

Immatics
Director, CMC Commercial Strategy
Dr. Pinar Cicalese is the Director of CMC Commercial Strategy at Immatics for adoptive cell therapies targeting various solid cancers. Pinar has nearly 20 years of experience in early-stage development through launch and growth of biological assets in companies of various sizes. Before joining Immatics, she was responsible for GlaxoSmithKline Cell and Gene Therapy platform manufacturing and supply strategy. Prior to this she led a Manufacturing Science and Technology group in GlaxoSmithKline delivering many late-stage and commercial Biopharmaceutical assets. Pinar holds a PhD in Chemical Engineering from Drexel University and was a Fulbright scholar during her PhD studies.

Related Articles

Delivering Curative Therapies: Autologous vs. Allogeneic Supply Chains
Features
Delivering Curative Therapies: Autologous vs. Allogeneic Supply Chains

Advanced therapy medicinal products (ATMPs) are one of the most promising developments in the pharmaceutical and biotech industries in recent decades. Although there is a great promise to treat and even cure many diseases with these products, there are also unique challenges, especially with their supply chains.